Jouary, T.
23  results:
Search for persons X
?
1

[New guidelines for stage III melanoma (the French Cutaneou..:

Guillot, B ; Dupuy, A ; Pracht, M...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annder.2019.01.011.  , 2019
 
?
2

[New guidelines for stage III melanoma (the French Cutaneou..:

Guillot, B ; Dupuy, A ; Pracht, M...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annder.2019.01.011.  , 2019
 
?
3

[New guidelines for stage III melanoma (the French Cutaneou..:

Guillot, B ; Dupuy, A ; Pracht, M...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annder.2019.01.011.  , 2019
 
?
4

[New guidelines for stage III melanoma (the French Cutaneou..:

Guillot, B ; Dupuy, A ; Pracht, M...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.annder.2019.01.011.  , 2019
 
?
 
?
7

Dabrafenib plus trametinib versus dabrafenib monotherapy in..:

Long, GV ; Flaherty, KT ; Stroyakovskiy, D...
Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 28 (7), pp. 1631 - 1639.  , 2017
 
?
9

First-in-human phase I study of the DNA-repair inhibitor DT..:

Le Tourneau, C ; Dreno, B ; Kirova, Y...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891504/.  , 2016
 
?
10

Hepatic intra-arterial versus intravenous fotemustine in pa..:

Leyvraz, S ; Piperno-Neumann, S ; Suciu, S...
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/7394.  , 2014
 
?
11

Hepatic intra-arterial versus intravenous fotemustine in pa..:

Leyvraz, S ; Piperno-Neumann, S ; Suciu, S...
info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdt585.  , 2014
 
?
12

Sorafenib and dacarbazine as first-line therapy for advance..:

Eisen, T ; Marais, R ; Affolter, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172912.  , 2011
 
?
13

Comprehensive association analysis of candidate genes for g..:

Birlea, S.A ; Jin, Y ; Bennett, D.C...
https://eprints.whiterose.ac.uk/110880/1/nihms304951.pdf.  , 2011
 
?
 
?
15

The Advantages of Targeted Protein Degradation Over Inhibit..:

Cromm, Philipp M ; Crews, Craig M ; Mainolfi, Nello...
Cromm , P M , Crews , C M , Mainolfi , N , Rasmusson , T , Poulikakos , P I , Zhang , C , Bollag , G , Shokat , K M , Rosen , N , Crews , C M , Agianian , B , Gavathiotis , E , Raina , K , Crews , C M , Durrant , D E , Morrison , D K , Neklesa , T K , Winkler , J D , Crews , C M , Chang , F , Steelman , L S , Lee , J T , Shelton , J G , Navolanic , P M , Blalock , W L , Franklin , R A , McCubrey , J A , Burslem , G M , Smith , B E , Lai , A C , Jaime-Figueroa , S , McQuaid , D C , Bondeson , D P , Toure , M , Dong , H , Qian , Y , Wang , J , Crew , A P , Hines , J , Crews , C M , Sanchez , J N , Wang , T , Cohen , M S , Shelledy, PharmD , L , Roman, PharmD, BCOP , D , Davies , H , Bignell , G R , Cox , C , Stephens , P , Edkins , S , Clegg , S , Teague , J , Woffendin , H , Garnett , M J , Bottomley , W , Davis , N , Dicks , E , Ewing , R , Floyd , Y , Gray , K , Hall , S , Hawes , R , Hughes , J , Kosmidou , V , Menzies , A , Mould , C , Parker , A , Stevens , C , Watt , ....  , 2018
 
1-15